- Home
- GAME vs VOR Comparison
GAME vs VOR Comparison
Compare GAME & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- VOR
- Stock Information
- Founded
- GAME 2011
- VOR 2015
- Country
- GAME United States
- VOR United States
- Employees
- GAME N/A
- VOR N/A
- Industry
- GAME
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- VOR Health Care
- Exchange
- GAME Nasdaq
- VOR Nasdaq
- Market Cap
- GAME 27.2M
- VOR 22.1M
- IPO Year
- GAME 2009
- VOR 2021
- Fundamental
- Price
- GAME $0.85
- VOR $0.22
- Analyst Decision
- GAME Strong Buy
- VOR Buy
- Analyst Count
- GAME 3
- VOR 6
- Target Price
- GAME $3.67
- VOR $7.20
- AVG Volume (30 Days)
- GAME 433.5K
- VOR 5.0M
- Earning Date
- GAME 05-15-2025
- VOR 05-14-2025
- Dividend Yield
- GAME N/A
- VOR N/A
- EPS Growth
- GAME N/A
- VOR N/A
- EPS
- GAME N/A
- VOR N/A
- Revenue
- GAME $99,579,536.00
- VOR N/A
- Revenue This Year
- GAME $6.08
- VOR N/A
- Revenue Next Year
- GAME $21.94
- VOR N/A
- P/E Ratio
- GAME N/A
- VOR N/A
- Revenue Growth
- GAME 77.06
- VOR N/A
- 52 Week Low
- GAME $0.50
- VOR $0.13
- 52 Week High
- GAME $1.43
- VOR $1.80
- Technical
- Relative Strength Index (RSI)
- GAME 58.35
- VOR 34.09
- Support Level
- GAME $0.86
- VOR $0.22
- Resistance Level
- GAME $0.92
- VOR $0.24
- Average True Range (ATR)
- GAME 0.07
- VOR 0.02
- MACD
- GAME 0.01
- VOR 0.02
- Stochastic Oscillator
- GAME 50.74
- VOR 78.40
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.